Skip to content

Merck snags Chinese obesity drug in nearly $2 billion deal


Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More]

Leave a Reply

Your email address will not be published. Required fields are marked *